Ilvico Tablets

Selected form

Method of action: Anthelmintic

Treatment option: Pain/ Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ilvico Tablets

Property	Description
Active Ingredients	Brompheniramine, Caffeine, Propyphenazone, Quinine, Salicylamide, Vitamin C
Form	Oral Tablet (Multi-component formulation)
Pharmacological Class	Analgesic, Antipyretic, Antihistamine, CNS Stimulant Combination
Common Purpose	Symptomatic relief of general discomforts
Origin	Synthetic and Derived

What Type of Medicine is Ilvico Tablets?

Ilvico Tablets is a pharmaceutical preparation classified as a multi-component formulation, delivered as an oral tablet for systemic action. This specific composition, combining six distinct active ingredients, sets it apart from simpler two or three-component remedies, as its design focuses on simultaneously addressing a wider array of discomforts. Its integrated nature places it within a combined therapeutic category that includes Analgesics, Antipyretics, and Antihistamines. The final product represents a synthetic and derived complex, combining chemically produced pharmacological agents with the essential nutrient Ascorbic acid (Vitamin C), a recognized approach in supportive illness management.

Key Active Components and High-Level Composition

The formulation's action is defined by its six core substances, creating a multi-targeted approach to relief. Brompheniramine maleate is a first-generation Histamine H1 Antagonist, an agent that diminishes symptoms associated with histamine release, such as nasal discharge. The core pain- and fever-reducing agents, Propyphenazone and Salicylamide, are categorized as Other Analgesics and Antipyretics. Propyphenazone, a pyrazolone derivative, is an analgesic often integrated into complex preparations to effectively manage generalized aches and discomforts. Additionally, the inclusion of Caffeine, a known Central Nervous System (CNS) Stimulant, is a differentiating feature intended to counter the sedative effects commonly associated with first-generation antihistamines.

General Therapeutic Goal and Combined Action

The general therapeutic purpose of Ilvico Tablets is to achieve symptomatic mitigation by easing varied physical discomforts concurrently, often in a typical use scenario like managing the overall feeling of being unwell associated with minor viral infections. The blend is structured for multi-targeted action, providing antipyresis (fever reduction) and analgesia (pain relief) through its active compounds. Furthermore, the mild stimulating effect of Caffeine helps to counter feelings of lethargy and fatigue, collectively supporting the patient's immediate comfort and general functional capacity.

Regulatory References

EDQM Evidence-based Classification Review (ATC N02B)

What side effects are possible with Ilvico Tablets?

Possible Side Effects and Safety Information

The safety profile of this multi-component formulation is officially documented by health regulatory agencies, with potential adverse reactions classified by frequency and affected body system. These classifications are based on observed data from clinical use and post-marketing surveillance.

Frequency-Classified Adverse Reactions

Adverse reactions that are Common (may affect up to 1 in 10 people) typically include sedation or somnolence (drowsiness), dry mouth, dizziness, and nervousness or insomnia. Effects classified as Uncommon or Rare may affect the gastrointestinal, dermatological, and cardiovascular systems.

System-Organ Classes and Serious Reactions

Side effects are officially grouped into System-Organ Classes, such as Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Blood and Lymphatic System Disorders. The label highlights specific, rare, but medically significant events. These serious adverse reactions include blood dyscrasias such as agranulocytosis and severe, potentially life-threatening hypersensitivity reactions (anaphylaxis or severe skin conditions).

Population-Specific Safety Considerations

The official documentation specifies safety considerations for certain patient groups. Older adults may have an increased potential for experiencing anticholinergic effects, such as urinary retention or confusion. Caution is officially recommended for patients with pre-existing hepatic or renal impairment, and specific dosage adjustments may be necessary due to potential impaired clearance. The product's safety profile is constrained by limitations such as avoiding use in cases of severe organ impairment or certain conditions like narrow-angle glaucoma.

Safety-Related Constraints

The label includes high-level constraints, notably advising against concurrent use with other products containing the same or similar active components (e.g., other analgesics or antihistamines) to prevent exceeding safe limits. Furthermore, official documentation notes that central nervous system depressants, including alcohol, may potentiate sedative effects.

Overdose and Emergency Response

Overdosage of Ilvico Tablets, a multi-component formulation, presents with documented multi-systemic effects. Initial manifestations often include nausea, vomiting, and central nervous system effects such as drowsiness, confusion, or, paradoxically, restlessness and hyperpyrexia. The presence of the Quinine component introduces the risk of cinchonism, defined by tinnitus, vertigo, and visual disturbances like blurred vision or constriction of visual fields.

Regulatory documents classify several severe and potentially life-threatening outcomes. These include cardiotoxicity, which can lead to QRS/QT prolongation and ventricular arrhythmias, and significant neurological effects such as seizures and coma. In severe cases, blindness is a noted risk associated with Quinine toxicity.

Due to these serious risks, government regulatory labeling mandates immediate action. Seek immediate medical attention must be pursued for any suspected overdosage, even if symptoms are not yet apparent. Individuals must immediately go to a medical center or contact emergency services.

Management is primarily symptomatic and supportive. Hospitalization is often required for continuous cardiac monitoring (serial ECGs) and observation for a minimum of six hours. Specific interventions, such as multiple-dose activated charcoal, are documented for large ingestions. Population-specific warnings note an increased risk of toxicity in children (paradoxical excitation) and in patients with underlying conditions like G6PD deficiency.

Therapeutic Uses of Ilvico Tablets

The medicine is commonly used for supportive symptomatic relief in conditions presenting with acute episodes of viral illness. Its primary therapeutic application is in easing the symptoms associated with the common cold, influenza, and general upper respiratory tract infections.

Symptom Domains and Benefits

Ilvico Tablets is applied in addressing symptom clusters that may appear suddenly or intensify over time, including systemic discomfort like fever and pain (such as headache and body aches), as well as specific manifestations like a runny nose and sneezing. Furthermore, the formulation supports the patient during difficult episodes by easing distress. The medicine is relevant in contexts involving heightened systemic burden where supportive symptomatic assistance is needed.

Quick Fact: Relief for Multi-Symptom Discomfort The combination formula may assist with easing the overall symptom burden, helping patients address symptom clusters that interfere with daily comfort.

“The medicine may be part of symptomatic management to address illness-related lethargy and fatigue, supporting the patient during difficult episodes.”

Regulatory References

Summary of Product Characteristics from the HPRA

Eligibility and Restrictions for Use

Who Can and Cannot Use Ilvico Tablets?

Eligibility for Ilvico Tablets (Paracetamol, Caffeine, and Brompheniramine formulation) is defined by official regulatory documentation and is strictly based on age, existing health conditions, and physiological state.

Absolute Contraindications (Must Not Use)

Population/Condition	Restriction
Age	Children less than 12 years old
Organ Function	Patients with severe hepatic impairment or severe renal impairment
Comorbidities	Patients with peptic ulcers, narrow-angle glaucoma, tachyarrhythmias, haemophilia, or conditions causing urinary retention
Concomitant Use	Patients taking or recently having taken Monoamine Oxidase Inhibitors (MAOIs) in the past 14 days

Restricted and Conditional Use

Use is not recommended in pregnant or breastfeeding women and should only occur if advised by a physician. Caution is required for patients with non-severe heart, lung, kidney, or liver problems, asthma, hyperthyroidism, or specific metabolic disorders like G6PD deficiency. Additionally, use in frail or elderly subjects may require a reduction in the recommended amount or frequency of administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile based on the combined action of its six active components. These interactions primarily involve pharmacokinetic modification, pharmacodynamic potentiation, and documented contraindicated combinations.

Pharmacodynamic and Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a contraindicated combination, as these drugs intensify the anticholinergic and CNS effects from the Brompheniramine component. Additionally, due to the Quinine component, co-administration with medicinal products known to prolong the QT interval (e.g., Astemizole, Pimozide) should be avoided. A pharmacodynamic interaction exists with alcohol and other Central Nervous System (CNS) depressants, resulting in additive effects that increase sedation. The analgesic components, Propyphenazone and Salicylamide, increase the caution required with oral anticoagulants, which may heighten the risk of bleeding or hemorrhage.

Metabolic and Exposure-Altering Interactions

The Quinine component acts as an inhibitor of drug-metabolizing enzymes, specifically documented as a moderate inhibitor of CYP3A4 and a weak inhibitor of CYP2D6. This pharmacokinetic interaction may lead to increased plasma concentrations of co-administered medicines that are substrates for these enzymes. Conversely, potent CYP3A4 inducers (e.g., Rifampin) can reduce Quinine exposure. The product also interacts with Digoxin by increasing its systemic exposure through transporter-mediated effects on biliary excretion.

Mechanism of Action

Modulating Central Pain and Thermoregulation Pathways

This action is primarily mediated by Paracetamol, which acts centrally within the nervous system. The mechanism involves the inhibition of cyclooxygenase ( COX) enzyme activity, particularly in the central nervous system, which decreases the synthesis of prostaglandins. This modification of key pathways that regulate nociception and body temperature results in adjustments to the thermal set point.

Antagonizing Histamine-Mediated Responses

The component Brompheniramine acts as an antagonist on histamine H1 receptors. By blocking the action of histamine—a key signaling mediator—this agent inhibits the cascading effects that influence vascular permeability and secretion, thereby regulating activity within targeted upper respiratory pathways.

Engaging Central Nervous System Stimulation

The ingredient Caffeine exerts its effect mainly by acting as an antagonist at adenosine receptors in the central nervous system. By blocking these receptors, caffeine enhances the release of stimulating neurotransmitters, leading to predictable physiological adjustments in central arousal and pain modulation pathways.

Dosage and Administration Information

The administration of Ilvico Tablets follows a precise oral dosing regimen. The medicine is delivered as an oral, film-coated tablet intended to be swallowed whole with water.

Dosing and Frequency

The standard labeled dosing for adults and adolescents aged 12 years and over specifies taking one to two tablets per single administration. This dosing pattern is designed for a frequency of up to three times daily. Standard guidelines specify that the maximum daily intake must not exceed six tablets within any 24-hour period. Patients are also instructed to avoid concurrently taking any other products that contain paracetamol, a primary component of this formulation, to prevent accidental over-exposure.

Administration Context and Duration

Regarding administration context, the tablets are intended to be taken preferably after a meal. The medicine is reserved exclusively for short-term use, and administration should not continue beyond three days without consulting a healthcare professional. These instructions establish the medicine's role strictly as an acute treatment, not a long-term therapy. Use is explicitly restricted in children under 12 years of age. It is also indicated that a reduction in dose or frequency may be appropriate for specific populations, including elderly individuals and patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ilvico Tablets

Evidence for use in Common Cold and Flu Symptoms

Research has examined the active ingredients in Ilvico Tablets in studies relevant to conditions characterized by acute or disruptive episodes, such as the common cold and flu-like illnesses. These studies often focus on outcomes related to physical discomfort and systemic or functional imbalance associated with body aches, fever, and nasal congestion.

Randomized controlled trials, which compare the treatment to an inactive substance (placebo) or other treatments, was studied for how these ingredients affect symptom intensity or variability over short time intervals. Research has explored temporary physiological imbalance, such as fever, and monitored how patient-reported outcomes describing perceived discomfort evolved during periods of increased symptom activity. Evidence suggests that the ingredients may be associated with changes in patient-reported outcomes describing perceived discomfort when applied in studies examining patient-reported experiences.

Evidence for use in Upper Respiratory Tract Infections

Studies was evaluated in research contexts involving fluctuating or unstable symptoms often associated with wider upper respiratory tract infections. This includes outcomes linked to inflammatory or irritative states such as a runny nose or scratchy throat. Research describes patterns observed in trials that evaluated the product's ingredients for outcomes reflecting daily functioning or activity level associated with conditions involving periods of heightened symptoms.

Long-term Studies and Follow-up

Research focusing specifically on the long-term effects are not fully established for the components of Ilvico Tablets, as these products was studied for short-term, acute relief. The studies typically observe responses over defined time intervals that are limited to a few days or weeks. Therefore, there is limited information for long-term outcomes concerning the daily or repeated use of this specific combination of ingredients. The follow-up durations were limited in most trials, and specific data on long-term outcomes for this acute combination data are still emerging or insufficient.

Evidence in Special Populations

Research has explored how the active ingredients was studied for in certain special populations, such as older adults and individuals with pre-existing conditions. For instance, studies involving individuals with comorbid conditions (other health issues) was observed in some studies and was associated with specific patterns. However, data for certain groups remain insufficient, meaning evidence quality may vary compared to the general adult population studied. Results apply only to the populations studied, and therefore, the knowledge base for children, pregnant individuals, or specific chronic conditions evidence is limited.

What is Still Uncertain about Ilvico Tablets

The research highlights what is known — and what is still uncertain — about the use of Ilvico Tablets. Subgroup findings are uncertain in many cases, and evidence quality varies across studies depending on their design and size. Certainty remains low for making definitive predictions about how an individual will respond. Findings were mixed in some research areas, and the extent to which the three ingredients work together compared to using them separately was observed in some studies but requires further research to confirm. Sample sizes were modest in some cases, and further research, including more robust trials, is ongoing for the specific three-ingredient combination.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ilvico Tablets (FAQ)

Q: Is Ilvico Tablets the same as paracetamol (acetaminophen)?

No, official product information indicates that Ilvico Tablets is a multi-component formulation. It contains paracetamol as one of its active substances, along with several other ingredients, such as caffeine and an antihistamine, which separates it from products that contain only paracetamol.

Q: What is the difference between Ilvico Tablets and a standard cold remedy?

Regulatory documents describe this medicine as having a combined therapeutic category, which includes Analgesic (pain relief), Antipyretic (fever reduction), and Antihistamine components. This multi-targeted composition is described as addressing multiple symptoms associated with cold and flu-like illnesses.

Q: What types of over-the-counter medicines should be avoided when taking Ilvico Tablets?

Official regulatory guidance advises against taking it alongside any other products that contain paracetamol, other analgesics, or similar antihistamines. Additionally, contraindications include co-administration with Monoamine Oxidase Inhibitors (MAOIs) or products known to prolong the QT interval.

Q: Is it normal to feel a bit restless after taking Ilvico Tablets?

Yes, official product information lists restlessness as a common side effect of the medicine. This effect is related to the medicine's components as described in the official product information.

Q: Does Ilvico Tablets interact with caffeine?

The tablets contain caffeine as one of the active ingredients. Official product information suggests that combining it with other sources of caffeine may increase the potential for stimulant-related effects, such as nervousness or insomnia.

Q: Can Ilvico Tablets be taken with other pain relievers?

Official regulatory instructions strictly advise against taking the tablets with any other products that contain paracetamol or other analgesics. This caution is in place due to the risk of exceeding the safe daily limit for the active ingredients.

Q: Is it true that Ilvico Tablets can affect sleep?

Yes, the official safety profile lists insomnia (difficulty sleeping) and nervousness as common adverse reactions. This potential effect is often linked to the stimulating ingredient in the medicine.

Q: What should I know about taking Ilvico Tablets if I have high blood pressure?

Official information notes that high blood pressure may occur as a common side effect. It also states that caution is required for people with high blood pressure or other existing heart-related issues, due to the presence of a CNS stimulant component.

Q: What is the role of each active component in Ilvico Tablets?

The formulation is designed for multi-targeted relief. The components are described as providing analgesia (pain relief) and antipyresis (fever reduction). The antihistamine component helps to mitigate cold symptoms like a runny nose, while the CNS stimulant component aims to counter feelings of lethargy.

Q: Can taking Ilvico Tablets affect lab test results?

Regulatory documents for multi-component formulations sometimes include standard warnings about laboratory testing. Official warnings state that co-administration may affect the results of certain laboratory tests, particularly those used to assess liver and kidney function.

Q: Are there any specific foods or drinks that interact with Ilvico Tablets?

Official warnings specifically state that a pharmacodynamic interaction exists with alcohol. This combination may result in additive effects, which can increase the feeling of sedation or drowsiness.

Q: Is the antihistamine component in Ilvico Tablets sedating?

Yes, sedation and somnolence (drowsiness) are listed in official documents as common adverse reactions. This type of effect is commonly associated with one of the components in the medicine.

Q: Does Ilvico Tablets contain aspirin?

The official active ingredients list does not include Aspirin (Acetylsalicylic acid). The tablets contain Salicylamide, which is chemically part of the salicylate drug class but is not Aspirin itself.

Q: Are there any known severe adverse reactions to Ilvico Tablets described in regulatory documents?

Yes, official safety documents highlight rare, medically significant events. These include serious effects such as blood dyscrasias (disorders of the blood cell components) and severe, potentially life-threatening hypersensitivity reactions, such as anaphylaxis or severe skin conditions.

Q: What are the non-active ingredients in Ilvico Tablets?

Official product information, such as the Patient Information Leaflet, provides a full list of inactive components. These non-active components, or excipients, may include substances commonly used in tablets like microcrystalline cellulose, hypromellose, and magnesium stearate.

Q: Is a prescription needed to buy Ilvico Tablets?

The medicine is generally classified as a non-prescription medicine. In the countries where it is officially registered, it is typically categorized as a Pharmacy-only medicine, which is generally available without a prescription.

Q: Is there a difference in strength between Ilvico Tablets sold in different countries?

Yes, variations have been observed in regulatory filings across different countries. These differences can include changes in the specific profile of active components or adjustments to the exact dosages of the ingredients.

How should Ilvico Tablets be stored and disposed of?

Storage and Disposal Instructions for Ilvico Tablets

The storage and disposal of Ilvico Tablets must strictly follow the requirements documented in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Temperature: The medicine must be stored at a temperature not exceeding 25 C.
Stability: Do not use the tablets after the expiry date printed on the carton and blister packaging.
Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Requirements

Restriction: The product must not be thrown away via wastewater or regular household waste.
Procedure: Users must consult a pharmacist on the correct method for disposing of unused or expired medicine according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Bulgaria

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z